Jeffrey Zwicker, MD
Enriched profileChief of the Hematology Service · Memorial Sloan Kettering Cancer Center
Jeffrey Zwicker is Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 250 publications with 8,754 citations (h-index 46); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 21 Oct 2026
Jeffrey Zwicker, M.D., is Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center. The public record shows 250 publications with 8,754 citations (h-index 46), centered on Venous Thromboembolism Diagnosis and Management, Blood Coagulation and Thrombosis Mechanisms, Platelet Disorders and Treatments. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 13 companies, 1 NIH-funded awards (2025–2026).
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Venous Thromboembolism Diagnosis and Management
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 21 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 33 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 93.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 21 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Isoquercetin in People With Ovarian Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- Isoquercetin in Sickle Cell Anemia
Sponsor: Jeffrey Zwicker, MD
- Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 21 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202513 payments$14,175openpaymentsdata.cms.gov ↗
- CSL BehringProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
100%Factor Xa inhibitor83.2%Eliquis75%Xarelto25%Part D<11 patientsLow Molecular Weight Heparin16.8%Enoxaparin Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 21 Oct 2026
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping
Sloan-Kettering Inst Can Research
FY2026$612,382R01AT013147 - Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping
Sloan-Kettering Inst Can Research
FY2025$631,382R01AT013147 - Biomarkers and mechanisms in cancer associated thrombosis
Beth Israel Deaconess Medical Center
FY2022$829,929U01HL143365
Congress activity
Updated 21 Oct 2026
46 congress contributions (2013–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract A113: Cachexia and Depression in Pancreatic Cancer (PC) Associate with Myeloid Inflammation and Tumor-Intrinsic Metabolic Stress
AACR (meeting unresolved)
AACR2025Co-author - CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 21 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Clinically Relevant Outcomes With Romiplostim in Patients With Solid Tumors and Persistent Chemotherapy Induced Thrombocytopenia.
American journal of hematology
Article2026 - Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.
Science translational medicine
Article2026
Most-cited works
by citation count (OpenAlex)- 01Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismArticle1,633 citations2017
- 02
- 03
- 04
- 05Postdischarge thrombosis and hemorrhage in patients with COVID-19Article247 citations2020
Network
Updated 21 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 21 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jeffrey-zwicker-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 21 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Penn State College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - MMS
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- BS
University of California, Berkeley
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Chair
ISTH subcommittee on hemostasis and thrombosis in malignancy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗ - Former Vice-Chair and Chair
ASH subcommittee on thrombosis and vascular biology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Simon Karpatkin Plenary Lectureship
International Conference on Thrombosis and Hemostasis Issues in Cancer
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Gordon J. Strewler Mentorship of Resident Research Award
Department of Medicine, Beth Israel Deaconess Medical Center
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- Previously Associate Professor of Medicine
Harvard Medical School, and Chief of Benign Hematology, Beth Israel Deaconess Medical Center
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Joseph Antin, MD
Harvard University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center